Amgen Inc.
AMGNHealthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −14.0%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Free cash flow
Amgen Inc.'s free cash flow for fiscal 2025 was $8.1B, down 22.1% from $10.4B in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $9.6B. Over the past ten years it has ranged from $7.4B (fiscal 2023) to $10.6B (fiscal 2018); the current reading is higher than 18% of that period. Amgen Inc. ranks 9th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $8.1B | (22.07%) |
| FY2024 | $10.4B | 41.24% |
| FY2023 | $7.4B | (16.23%) |
| FY2022 | $8.8B | 4.82% |
| FY2021 | $8.4B | (15.25%) |
| FY2020 | $9.9B | 15.90% |
| FY2019 | $8.5B | (19.19%) |
| FY2018 | $10.6B | 0.43% |
| FY2017 | $10.5B | 9.33% |
| FY2016 | $9.6B | 2.18% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $3.7B | 4.73% |
| Jun 2026 | $3.5B | 136.22% |
| Mar 2026 | $1.5B | 53.69% |
| Dec 2025 | $961.0M | (77.38%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ABBV AbbVie Inc. compare | $18.9B |
| MRK Merck & Co., Inc. compare | $14.7B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. | $9.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| NVO Novo Nordisk A/S compare | $6.9B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement